EVOFEM BIOSCIENCES, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $20.2M | $19.4M | $18.2M | $16.8M | $8.2M | $446.0K | $0 |
| Cost of Revenue | — | $4.6M | $3.8M | $6.5M | $4.4M | $4.1M | $468.0K | $0 |
| Gross Profit | — | $15.6M | $15.5M | $11.7M | $12.4M | $4.2M | $-22.0K | $0 |
| Gross Margin | — | 77.1% | 80.2% | 64.3% | 73.8% | 50.8% | -4.9% | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | $1.8M | $2.9M | $25.0M | $33.1M | $17.1M | $22.2M |
| SG&A Expense | — | $7.4M | $11.6M | $15.0M | $27.6M | $24.7M | $30.1M | $20.3M |
| Operating Income | — | $3.4M | $-7.7M | $-17.8M | $-84.1M | $-166.8M | $-103.6M | $-52.7M |
| Operating Margin | — | 16.7% | -39.6% | -98.0% | -499.6% | -2,023.3% | -23,234.1% | — |
| Interest Expense | — | $2.4M | $2.2M | $2.3M | $2.2M | $2.7M | $2.1M | $0 |
| Pretax Income | — | $393.0K | $-8.9M | $53.0M | $-76.7M | $-205.2M | $-142.3M | $-80.0M |
| Income Tax Expense | — | $2.0K | — | $17.0K | $44.0K | $17.0K | $4.0K | $4.0K |
| Net Income | — | $391.0K | $-8.9M | $53.0M | $-76.7M | $-205.2M | $-142.3M | $-80.0M |
| Net Margin | — | 1.9% | -45.8% | 290.8% | -455.5% | -2,489.0% | -31,907.8% | — |
| EPS (Basic) | — | $0.00 | $0.00 | $0.13 | $-0.12 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | — | $0.00 | $0.00 | $0.00 | $-0.12 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 132.5M | 123.7M | 6.40B | 386.1M | 79.22B | 83.08B | 639.34B | 458.27B |
| Shares Outstanding (Diluted) | 132.5M | 6.42B | 6.40B | 78.72B | 79.22B | 83.08B | 639.34B | 458.27B |
| Dividends Per Share | — | — | — | — | — | — | — | — |